Mepolizumab induced palmoplantar psoriasis: A case report

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Atopic dermatitis and asthma involve T helper (Th)-2 lymphocytes and related cytokines.
• Psoriasis results from Th-17 and Th-1 lymphocyte recruitment.
• Mepolizumab targets interleukin (IL)-5, a key Th-2 cytokine, for asthma treatment.

Observation:

• A 59-year-old patient developed psoriasiform lesions on palms after mepolizumab therapy for asthma.
• This adverse effect is hypothesized to result from parallel cytokine cascade activation following IL-5 blockade.
• The patient's lesions were successfully treated with a combination of topical calcipotriol and betamethasone ointment.

Findings:

• Mepolizumab therapy, while targeting IL-5 for asthma, may lead to unexpected dermatological conditions.
• The development of psoriasis-like lesions suggests a complex interplay within the immune system's cytokine networks.
• Topical corticosteroids and vitamin D analogs can effectively manage these therapy-induced skin conditions.

Implications:

• Further investigation into the immunological effects of inhibiting specific inflammatory mediators is warranted.
• Early recognition of adverse effects from targeted immunotherapies is crucial for patient management.
• Understanding cytokine cascade interactions can inform safer and more effective treatment strategies for immune-mediated diseases.